The Bombay High Court backed GSK’s Indian unit in its Paxil trademark dispute with Shreya Life Sciences. GSK argued that while Shreya secured the mark more than two decades ago, it never used it for pharmaceutical and medicinal preparations. That, GSK said, makes the registration liable for removal under Section 47 of the Trade Marks Act.
Swipe through stories, personalise your feed, and save articles for later — all on the app.
